Abstract
How single-chain variable fragments (scFvs) affect the functions of chimeric antigen receptors (CARs) has not been well studied. Here, the components of CAR with an emphasis on scFv were described, and then several methods to measure scFv affinity were discussed. Next, scFv optimization studies for CD19, CD38, HER2, GD2 or EGFR were overviewed, showing that tuning the affinity of scFv could alleviate the on-target/off-tumor toxicity. The affinities of scFvs for different antigens were also summarized to designate a relatively optimal working range for CAR design. Last, a synthetic biology approach utilizing a low-affinity synthetic Notch (synNotch) receptor to achieve ultrasensitivity of antigen-density discrimination and murine models to assay the on-target/off-tumor toxicity of CARs were highlighted. Thus, this review provides preliminary guidelines of choosing the right scFvs for CARs.
Similar content being viewed by others
Data availability
Not applicable.
References
June CH, Sadelain M (2018) Chimeric antigen receptor therapy. N Engl J Med 379:64–73
Vairy S, Garcia JL, Teira P, Bittencourt H (2018) CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia. Drug Des Dev Ther 12:3885–3898
Neelapu SS et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New Engl J Med 377:2531–2544
Jacobson CA et al (2020) Interim analysis of ZUMA-5: a phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL). J Clin Oncol 38
Morris EC, Neelapu SS, Giavridis T, Sadelain M (2021) Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 17:1–12
Maude SL, Barrett D, Teachey DT, Grupp SA (2014) Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 20:119–122
Schubert ML et al (2021) Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol 32:34–48
Qin JS et al (2020) Antitumor potency of an anti-CD19 chimeric antigen receptor T-cell therapy, lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib. J Immunother 43:107–120
Wang MH et al (2020) KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 382:1331–1342
Locke FL et al (2017) Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther 25:285–295
Yu SN, Yi M, Qin S, Wu KM (2019) Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol Cancer 18:125
Filley AC, Henriquez M, Dey M (2018) CART immunotherapy: development success, and translation to malignant gliomas and other solid tumors. Front Oncol 8:453
Lamers CHJ, Klaver Y, Gratama JW, Sleijfer S, Debets R (2016) Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells—a completed study overview. Biochem Soc T 44:951–959
Morgan RA et al (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18:843–851
Andrea AE, Chiron A, Bessoles S, Hacein-Bey-Abina S (2020) Engineering next-generation CAR-T cells for better toxicity management. Int J Mol Sci 21:8620
Dotti G, Gottschalk S, Savoldo B, Brenner MK (2014) Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 257:107–126
Hudecek M et al (2013) Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 19:3153–3164
Ahmed N et al (2010) HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res 16:474–485
Ghorashian S et al (2019) Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med 25:1408–1414
Drent E et al (2017) A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization. Mol Ther 25:1946–1958
Liu X et al (2015) Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res 75:3596–3607
Castellarin M et al (2020) A rational mouse model to detect on-target, off-tumor CAR T cell toxicity. Jci Insight 5:e136012
Richman SA et al (2018) High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model. Cancer Immunol Res 6:36–46
Caruso HG et al (2015) Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res 75:3505–3518
Hernandez-Lopez RA et al (2021) T cell circuits that sense antigen density with an ultrasensitive threshold. Science 371:1166–1171
Sadelain M, Brentjens R, Riviere I (2013) The basic principles of chimeric antigen receptor design. Cancer Discov 3:388–398
Becker MLB et al (1989) Expression of a hybrid immunoglobulin-T Cell-receptor protein in transgenic mice. Cell 58:911–921
Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 20:70–75
Finney HM, Akbar AN, Lawson ADG (2004) Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 172:104–113
Hong MH, Clubb JD, Chen YY (2020) Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell 38:473–488
Gross G, Waks T, Eshhar Z (1989) Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 86:10024–10028
Schmid DA et al (2010) Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol 184:4936–4946
Chmielewski M, Hombach A, Heuser C, Adams GP, Abken H (2004) T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol 173:7647–7653
Sharma P et al (2020) Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides. Proc Natl Acad Sci USA 117:15148–15159
Estep P et al (2013) High throughput solution-based measurement of antibody-antigen affinity and epitope binning. Mabs-Austin 5:270–278
Sadelain M (2015) CAR therapy: the CD19 paradigm. J Clin Invest 125:3392–3400
Brudno JN et al (2018) Clinical anti-lymphoma activity and toxicity of T cells expressing a novel anti-CD19 chimeric antigen receptor with fully-human variable regions. J Clin Oncol 36
Michelozzi IM et al (2020) The enhanced functionality of low-affinity CD19 CAR T cells is associated with activation priming and polyfunctional cytokine phenotype. Blood 136(Supplement 1):52–53
Hamieh M et al (2019) CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568:112–116
Gao ZT et al (2019) Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells. J Genet Genom 46:367–377
Ding Z et al (2021) CD38 multi-functionality in oral squamous cell carcinoma: prognostic implications, immune balance, and immune checkpoint. Front Oncol 11:687430
Ge Y et al (2019) CD38 affects the biological behavior and energy metabolism of nasopharyngeal carcinoma cells. Int J Oncol 54:585–599
Liao S et al (2014) CD38 is highly expressed and affects the PI3K/Akt signaling pathway in cervical cancer. Oncol Rep 32:2703–2709
de Weers M et al (2011) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 186:1840–1848
Guo YL et al (2020) Efficiency and side effects of anti-CD38 CAR T cells in an adult patient with relapsed B-ALL after failure of bi-specific CD19/CD22 CAR T cell treatment. Cell Mol Immunol 17:430–432
Krejcik J et al (2016) Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128:384–394
Mihara K et al (2009) Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-hodgkin lymphoma. J Immunother 32:737–743
Drent E et al (2019) Combined CD28 and 4-1BB costimulation potentiates affinity-tuned chimeric antigen receptor-engineered T cells. Clin Cancer Res 25:4014–4025
Garcia-Guerrero E, Sierro-Martinez B, Perez-Simon JA (2020) Overcoming chimeric antigen receptor (CAR) modified T-cell therapy limitations in multiple myeloma. Front Immunol 11:1128
Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M (2013) Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 31:71–75
Fedorov VD, Themeli M, Sadelain M (2013) PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med 5:215ra172
Szoor A et al (2020) Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies. Cancer Lett 484:1–8
Ahmed N et al (2009) Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther 17:1779–1787
Huszno J, Les D, Sarzyczny-Slola D, Nowara E (2013) Cardiac side effects of trastuzumab in breast cancer patients - single centere experiences. Wspolczesna Onkol 17:190–195
Sujjitjoon J et al (2021) GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma—assessing tumor and T cell interaction. Transl Oncol 14:100971
Golinelli G et al (2020) Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors. Cancer Gene Ther 27:558–570
Nazha B, Inal C, Owonikoko TK (2020) Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front Oncol 10:1000
Yu AL et al (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363:1324–1334
Ari P, Kars M, Meany H, Pestieau S (2018) Treatment of transient peripheral neuropathy during chimeric 14.18 antibody therapy in children with neuroblastoma: a case series. J Pediat Hematol Oncol 40:E113–E116
Richman SA, Milone MC (2018) Neurotoxicity associated with a high-affinity GD2 CAR-response. Cancer Immunol Res 6:496–497
Majzner RG, Weber EW, Lynn RC, Xu P, Mackall CL (2018) Neurotoxicity associated with a high-affinity GD2 CAR-letter. Cancer Immunol Res 6:494–495
Ke EE, Wu YL (2016) EGFR as a pharmacological target in EGFR-mutant non-small-cell lung cancer: where do we stand now? Trends Pharmacol Sci 37:887–903
Li H et al (2018) Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice. Cell Death Dis 9:177
Feng K et al (2016) Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. Sci China Life Sci 59:468–479
Guo Y et al (2018) Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers. Clin Cancer Res 24:1277–1286
Liu Y et al (2020) Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial. Cytotherapy 22:573–580
Perez R, Moreno E, Garrido G, Crombet T (2011) EGFR-targeting as a biological therapy: understanding nimotuzumab’s clinical effects. Cancers 3:2014–2031
Caliendo F, Dukhinova M, Siciliano V (2019) Engineered cell-based therapeutics: synthetic biology meets immunology. Front Bioeng Biotech 7:43
Wu MR, Jusiak B, Lu TK (2019) Engineering advanced cancer therapies with synthetic biology. Nat Rev Cancer 19:187–195
Rafiq S, Hackett CS, Brentjens RJ (2020) Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol 17:147–167
Roybal KT et al (2016) Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164:770–779
Giavridis T et al (2018) CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med 24:731–738
Norelli M et al (2018) Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 24:739–748
Jayaraman J et al (2020) CAR-T design: elements and their synergistic function. EBioMedicine 58:102931
Orlando EJ et al (2018) Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med 24:1504
Sotillo E et al (2015) Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 5:1282–1295
Nijhof IS et al (2016) CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood 128:959–970
Ghose J et al (2018) Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology 7:e1486948
Li R, Ma C, Cai HG, Chen WQ (2020) The CAR T-Cell Mechanoimmunology at a Glance. Adv Sci 7:2002628
Fry TJ et al (2018) CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med 24:20
Long AH et al (2015) 4–1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21:581–590
Feucht J et al (2019) Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat Med 25:82–88
Acknowledgements
The authors would like to acknowledge the published work of many researchers whose work has relevance for this review, but were not cited because of space and our own limitations.
Funding
This research was funded by the National Natural Science Foundation of China Grants 31971324 (J.S.), 81973993 (X.G.) and 31971125 (C.Z.), by Zhejiang Provincial Natural Science Foundation Grants LR20H160003 (J.S.) and LY21H080002 (C.L.) and by the Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province JBZX-201904 (C.L.).
Author information
Authors and Affiliations
Contributions
Y.D., R.C. and J.S. wrote the manuscript. All the authors discussed and approved the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Ethical approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Duan, Y., Chen, R., Huang, Y. et al. Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy. Cell. Mol. Life Sci. 79, 14 (2022). https://doi.org/10.1007/s00018-021-04089-x
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00018-021-04089-x